SB 204990
Based on 26 publication(s) in Google Scholar
SB 204990 is a potent and specific inhibitor of ATP citrate lyase (ACLY) enzyme.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.75%
- No. CAS: 154566-12-8
- Fòrmula: C18H22Cl2O5
- Peso molecular:389.27
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-16107
BMS-303141ATP Citrate Lyase Inhibitor -
HY-127111
NDI-091143ATP Citrate Lyase Inhibitor -
HY-12357
Bempedoic acidACL Inhibitor/AMPK Activator -
HY-13215
AvasimibeACAT/SOAT Inhibitor -
HY-16901
FirsocostatACC Inhibitor -
HY-104032
Ac-CoA Synthase-IN-1ACSS2 Inhibitor -
HY-123986
CTPI-2SLC25A1 Inhibitor -
HY-13259
MG-132Proteasome Inhibitor -
HY-13433
ThapsigarginER Stress Inducer -
HY-15475
UK-5099Mitochondrial Pyruvate Carrier Inhibitor -
HY-13966
2-Deoxy-D-glucoseGlycolysis Inhibitor -
HY-12041
SP600125JNK Inhibitor
Publications Citing Use of MedChemExpress (MCE) SB 204990
More- Nature. 2026 Jan;649(8098):1022-1031. [Abstract]
- Cell Metab. 2023 Jan 3;35(1):200-211.e9. [Abstract]
- Nat Protoc. 2024 May;19(5):1311-1347. [Abstract]
- Adv Sci (Weinh). 2026 Jun;13(35):e21458. [Abstract]
- Adv Sci (Weinh). 2025 Aug;12(31):e14367. [Abstract]
- Adv Sci (Weinh). 2023 Aug;10(23):e2301094. [Abstract]
- Cell Death Dis. 2025 Dec 18. [Abstract]
- Cell Death Dis. 2025 Apr 14;16(1):291. [Abstract]
- Pharmacol Res. 2021 Mar:165:105393. [Abstract]
- J Pharm Anal. 2024 Feb;14(2):244-258. [Abstract]
- Oncogene. 2025 Nov 28. [Abstract]
- Apoptosis. 2025 Feb;30(1-2):334-348. [Abstract]
- Int J Nanomedicine. 2024 Nov 4:19:11235-11255. [Abstract]
- JACC Basic Transl Sci. 2025 Jun 10;10(7):101301. [Abstract]
- EMBO Mol Med. 2024 Jul;16(7):1533-1559. [Abstract]
- Cell Rep. 2024 Nov 26;43(12):115015. [Abstract]
- Cell Rep. 2023 Jun 1;42(6):112583. [Abstract]
- Cell Rep. 2022 Feb 15;38(7):110391. [Abstract]
- Liver Int. 2023 Aug;43(8):1729-1740. [Abstract]
- Sci Rep. 2024 Nov 15;14(1):28193. [Abstract]
- Sci Rep. 2023 Oct 29;13(1):18549. [Abstract]
- Pathol Res Pract. 2020 Sep;216(9):153076. [Abstract]
- Front Oncol. 2021 Mar 17:11:642229. [Abstract]
- bioRxiv. 2026 Feb 1.
- bioRxiv. 2023 Jul 3.
- Research Square Preprint. 2022 Feb.
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Flow Cytometry
-
WB
-
Flow Cytometry
-
RT-PCR
Actividad biológica
Descripciòn
IC50 & Target
ACLY[1].
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
24 μM
Compound: 16; SB-204990
|
Antiproliferative activity against human A549 cells
Antiproliferative activity against human A549 cells
|
[PMID: 30195238] |
| PC-3 | IC50 |
26 μM
Compound: 16; SB-204990
|
Antiproliferative activity against human PC3 cells
Antiproliferative activity against human PC3 cells
|
[PMID: 30195238] |
| SK-OV-3 | IC50 |
53 μM
Compound: 16; SB-204990
|
Antiproliferative activity against human SKOV3 cells
Antiproliferative activity against human SKOV3 cells
|
[PMID: 30195238] |
In Vitro
SB204990 (SB) is a specific inhibitor of ACLY enzyme. SB204990 treatment leads to a decrease in cytosolic Ac-CoA level and is thus expected to decrease acetylated and active β-catenin levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 154566-12-8
-
Appearance Solid
-
Peso molecular 389.27
-
Fòrmula C18H22Cl2O5
-
Color White to off-white
-
SMILES
O=C(O)C[C@]1(O)C(O[C@H](CCCCCCC2=CC=C(Cl)C=C2Cl)C1)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (26)
-
Journal Impact Factor
-
Most Recent
-
Nature
2026 Jan;649(8098):1022-1031. PMID: 41225001
SB 204990 purchased from MedChemExpress. Usage Cited in: Nature. 2026 Jan;649(8098):1022-1031. [Abstract]
SB 204990 (SB, 100 μM, 16 h) reduced cytosolic AcCoA levels in HeLa-tet-on-mt-Keima cells.
SB 204990 purchased from MedChemExpress. Usage Cited in: Nature. 2026 Jan;649(8098):1022-1031. [Abstract]
SB 204990 (SB, 100 μM, 16 h) enhanced mitophagy, as indicated by an increase in the acidic mt-Keima signal in HeLa-tet-on-mt-Keima cells.
SB 204990 purchased from MedChemExpress. Usage Cited in: Nature. 2026 Jan;649(8098):1022-1031. [Abstract]
SB 204990 (SB, 100 μM, 16 h) increased LC3 expression and decreased TIM23 and MT-CO2 levels in HeLa-tet-on-mt-Keima cells.
SB 204990 purchased from MedChemExpress. Usage Cited in: Nature. 2026 Jan;649(8098):1022-1031. [Abstract]
SB 204990 (SB, 100 μM, 16 h) increased the acidic mt-Keima signal in MCF7 and A549 cells.
SB 204990 purchased from MedChemExpress. Usage Cited in: Nature. 2026 Jan;649(8098):1022-1031. [Abstract]
SB 204990 (SB, 100 μM, 16 h) decreased mitochondrial mass in MCF7, A549, and HeLa cells.
-
Cell Metab
Ultrasensitive sensors reveal the spatiotemporal landscape of lactate metabolism in physiology and disease. [Abstract]2023 Jan 3;35(1):200-211.e9. PMID: 36309010 -
Nat Protoc
Comprehensive multiscale analysis of lactate metabolic dynamics in vitro and in vivo using highly responsive biosensors. [Abstract]2024 May;19(5):1311-1347. PMID: 38307980 -
Adv Sci (Weinh)
Extracellular Vesicle-Transferred ATP-Citrate Lyase Induces Monocyte Differentiation Toward Tumor-Associated Macrophages and Fuels Hepatocellular Carcinoma Progression. [Abstract]2026 Jun;13(35):e21458. PMID: 41995119 -
Adv Sci (Weinh)
The Nuclear Localization of ACLY Guards Early Embryo Development Through Recruiting P300 and HAT1 to Promote Histone Acetylation and Transcription. [Abstract]2025 Aug;12(31):e14367. PMID: 40470746 -
Adv Sci (Weinh)
MSL1 Promotes Liver Regeneration by Driving Phase Separation of STAT3 and Histone H4 and Enhancing Their Acetylation. [Abstract]2023 Aug;10(23):e2301094. PMID: 37279389 -
Cell Death Dis
ACSS1 co-opts acetyl-CoA metabolism to drive DNA repair and undermine radiotherapy efficacy in breast cancer. [Abstract]2025 Dec 18. PMID: 41413018 -
Cell Death Dis
A targetable antioxidant defense mechanism to EZH2 inhibitors enhances tumor cell vulnerability to ferroptosis. [Abstract]2025 Apr 14;16(1):291. PMID: 40229247 -
Pharmacol Res
Pharmacological induction of mesenchymal-epithelial transition via inhibition of H2S biosynthesis and consequent suppression of ACLY activity in colon cancer cells. [Abstract]2021 Mar:165:105393. PMID: 33484818 -
J Pharm Anal
Tanshinone IIA ameliorates energy metabolism dysfunction of pulmonary fibrosis using 13C metabolic flux analysis. [Abstract]2024 Feb;14(2):244-258. PMID: 38464785 -
Oncogene
SLC7A5-ERBB2 axis drives olaparib resistance via de novo lipid synthesis in ovarian cancer. [Abstract]2025 Nov 28. PMID: 41315667 -
Apoptosis
Mitochondrial CLPB is a pro-survival factor at the onset of granulocytic differentiation of mouse myeloblastic cells. [Abstract]2025 Feb;30(1-2):334-348. PMID: 39644357 -
Int J Nanomedicine
A Graphene-Based Lipid Modulation Nanoplatform for Synergetic Lipid Starvation/Chemo/Photothermal Therapy of Oral Squamous Cell Carcinoma. [Abstract]2024 Nov 4:19:11235-11255. PMID: 39524917 -
JACC Basic Transl Sci
ATP-Citrate Lyase Supports Cardiac Function and NAD+/NADH Balance and Is Depressed in Human Failing Myocardium. [Abstract]2025 Jun 10;10(7):101301. PMID: 40499285 -
EMBO Mol Med
FADS1/2 control lipid metabolism and ferroptosis susceptibility in triple-negative breast cancer. [Abstract]2024 Jul;16(7):1533-1559. PMID: 38926633 -
Cell Rep
2024 Nov 26;43(12):115015. PMID: 39602308 -
Cell Rep
2023 Jun 1;42(6):112583. PMID: 37267106 -
Cell Rep
2022 Feb 15;38(7):110391. PMID: 35172156 -
Liver Int
Inhibition of ACSS2 attenuates alcoholic liver steatosis via epigenetically regulating de novo lipogenesis. [Abstract]2023 Aug;43(8):1729-1740. PMID: 37183518 -
Sci Rep
Contribution of glucose and glutamine to hypoxia-induced lipid synthesis decreases, while contribution of acetate increases, during 3T3-L1 differentiation. [Abstract]2024 Nov 15;14(1):28193. PMID: 39548264 -
Sci Rep
Lipidome and metabolome analyses reveal metabolic alterations associated with MCF-7 apoptosis upon 4-hydroxytamoxifen treatment. [Abstract]2023 Oct 29;13(1):18549. PMID: 37899460 -
Pathol Res Pract
2020 Sep;216(9):153076. PMID: 32825949 -
Front Oncol
Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K-AKT Pathway and Activating the AMPK-ROS Pathway. [Abstract]2021 Mar 17:11:642229. PMID: 33816292 -
-
-
Solvente y solubilidad
In Vitro:
DMSO : ≥ 100 mg/mL (256.89 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.34 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.34 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (272 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Shares BH, et al. Active mitochondria support osteogenic differentiation by stimulating β-catenin acetylation. J Biol Chem. 2018 Oct 12;293(41):16019-16027. [Content Brief]
[2]. Pearce NJ, et al. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem J. 1998 Aug 15;334 ( Pt 1):113-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5689 mL | 12.8446 mL | 25.6891 mL | 64.2228 mL |
| 5 mM | 0.5138 mL | 2.5689 mL | 5.1378 mL | 12.8446 mL | |
| 10 mM | 0.2569 mL | 1.2845 mL | 2.5689 mL | 6.4223 mL | |
| 15 mM | 0.1713 mL | 0.8563 mL | 1.7126 mL | 4.2815 mL | |
| 20 mM | 0.1284 mL | 0.6422 mL | 1.2845 mL | 3.2111 mL | |
| 25 mM | 0.1028 mL | 0.5138 mL | 1.0276 mL | 2.5689 mL | |
| 30 mM | 0.0856 mL | 0.4282 mL | 0.8563 mL | 2.1408 mL | |
| 40 mM | 0.0642 mL | 0.3211 mL | 0.6422 mL | 1.6056 mL | |
| 50 mM | 0.0514 mL | 0.2569 mL | 0.5138 mL | 1.2845 mL | |
| 60 mM | 0.0428 mL | 0.2141 mL | 0.4282 mL | 1.0704 mL | |
| 80 mM | 0.0321 mL | 0.1606 mL | 0.3211 mL | 0.8028 mL | |
| 100 mM | 0.0257 mL | 0.1284 mL | 0.2569 mL | 0.6422 mL |
SB 204990 Related Classifications
HY-16450 Related Classifications
Powered by Bioz